血清基质细胞衍生因子-1水平对阿卡波糖治疗初发2型糖尿病效果的影响

Effect of serum stromal cell derived factor-1 level on the clinical efficacy of Acarbose in the treatment of newly diagnosed type 2 diabetes

目的探讨血清基质细胞衍生因子-1(SDF-1)水平对阿卡波糖治疗初发2型糖尿病效果的影响。方法选取2013年6月~2015年12月广西壮族自治区百色市人民医院内分泌科收治的初发2型糖尿病患者64例为研究对象。所有患者均予以口服阿卡波糖50 mg,每日3次,疗程持续6个月。采用酶联免疫吸附试验测定患者治疗前SDF-1水平,并以中位数155.86 pg/m L为分界值,将患者分为高SDF-1组(21例)和低SDF-1组(43例),比较不同SDF-1水平对阿卡波糖治疗初发2型糖尿病临床效果的影响。结果低SDF-1组的总有效率为97.67%,显著高于高SDF-1组的80.95%,差异有统计学意义(P<0.05)。低SDF-1组空腹血糖和餐后2 h血糖均明显低于高SDF-1组,差异有统计学意义(P<0.05)。两组肌酐、尿素氮比较,差异无统计学意义(P>0.05)。结论低水平SDF-1的初发2型糖尿病患者予以阿卡波糖治疗的临床效果更为良好。

Objective To explore the effect of serum stromal cell derived factor-1 （SDF-1） level on the clinical effica- cy of acarbose in the treatment of newly diagnosed type 2 diabetes. Methods 64 cases of newly diagnosed type 2 dia- betes from June 2013 to December 2015 in Department of Endocrinology, People＇s Hospital of Baise City, Guangxi Zhuang Autonomous Region were selected as study subjects. All patients were given 50 mg Acarbose, 3 times a day and lasted for 6 months. Enzyme linked immunosorbent assay was used to measure the level of SDF-1 before treatment, and the median 155.86 pg/mL was used as the cut-off value. The patients were further.divided into high SDF-1 group （21 cases） and low SDF-1 group （43 cases）. The effects of SDF-1 levels on clinical efficacy of Acarbose in the treat- ment of type 2 diabetes were compared. Results Total effective rate in low SDF-1 group was 97.67%, significantly higher than that in high SDF-1 group （80.95%） （P 〈 0.05）. Fasting blood glucose and 2 h postprandial blood glucose in lower SDF-1 group were significantly lower than those in high SDF-1 group （P 〈 0.03）. There was no significant differ- ence in serum creatinine and urea nitrogen between two groups （P 〉 0.05）. Conclusion Clinical efficacy of Acarbose is much better in the newly diagnosed type 2 diabetic patients with low level of SDF-1.